Group 1 - The company will hold a collective performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [1][2] - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, and it will be conducted in an online text interaction format [1][2] - Investors can submit questions from September 9, 2025, to September 15, 2025, before 16:00, through the Roadshow Center website or via the company's email [2][3] Group 2 - Key participants in the meeting will include the Chairman and General Manager Yuan Jiandong, Financial Director Zou Yuanlai, Independent Director Xu Dongdong, and Board Secretary Ding Nan [2] - After the briefing, investors can view the meeting's proceedings and main content on the Shanghai Stock Exchange Roadshow Center [3]

Group 1 - The company issued 4.65 million convertible bonds with a total value of 465 million RMB, which began trading on January 27, 2022 [1] - The conversion price of the bonds was adjusted from 35.56 RMB to 35.05 RMB on December 6, 2022, due to the company's annual equity distribution [3] - The conversion price will continue to be adjusted based on annual equity distributions, with the next adjustment scheduled for July 2024 [3] Group 2 - The redemption terms allow the company to redeem the bonds if the stock price remains above 130% of the conversion price for at least 15 out of 30 trading days [5] - The company will decide on redemption based on stock performance from August 22 to September 4, 2025, with a potential trigger for the redemption clause [5]

Core Viewpoint - On September 5, 2023, Borui Pharmaceutical experienced significant trading activity, with a total of 266,900 shares traded on the block trading platform, amounting to 24.6483 million yuan, indicating notable investor interest [1] Trading Activity Summary - The trading included three transactions, with a total volume of 266,900 shares and a total transaction value of 24.6483 million yuan [1] - Among the transactions, two were conducted at a discount, with the highest discount rate reaching 10.00% [1] - Institutional participation was noted in one of the transactions, with a total transaction amount of 5.2392 million yuan, resulting in a net purchase of 5.2392 million yuan [1] Recent Performance Metrics - Over the past three months, Borui Pharmaceutical has recorded a total of 22 block trades, with a cumulative transaction value of 241 million yuan [1] - The closing price on September 5 was 97.02 yuan, reflecting a 9.50% increase, with a daily turnover rate of 4.20% and a total trading volume of 1.651 billion yuan [1] - The net inflow of main funds for the day was 306 million yuan, while the stock has seen a cumulative increase of 0.57% over the past five days, with a total net outflow of 165 million yuan during the same period [1] Margin Financing Data - The latest margin financing balance for Borui Pharmaceutical stands at 2.175 billion yuan, having decreased by 118 million yuan over the past five days, representing a decline of 5.15% [1]

Group 1 - The company, Borui Pharmaceutical, announced its participation in the 2025 semi-annual performance briefing for the innovative drug industry organized by the Shanghai Stock Exchange [2] - The event is scheduled for September 16, 2025, from 15:00 to 17:00 [2] - This participation indicates the company's engagement with investors and stakeholders in the innovative drug sector [2]

Market Overview - The net inflow of main funds in the Shanghai and Shenzhen markets reached 44.53 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 1.295 billion yuan [1] - A total of 275 stocks experienced net inflows, while 311 stocks saw net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 562 stocks rose, with 7 stocks hitting the daily limit, including Yuchan Intelligent and Xiamen Tungsten [1] - The top three stocks with the highest net inflow were: - Lanke Technology: 430.46 million yuan - Borui Pharmaceutical: 306.50 million yuan - Tianyue Advanced: 218.43 million yuan [2] Continuous Fund Flow - There are 33 stocks with continuous net inflows for more than three trading days, with Hanwujing leading at 13 consecutive days [2] - Conversely, 166 stocks experienced continuous net outflows, with Huate Gas leading at 15 consecutive days [2] Key Stocks with Significant Fund Inflows - The following stocks had notable net inflows: - Lanke Technology: 430.05 million yuan, with a flow rate of 8.09% and a price increase of 5.41% [2] - Borui Pharmaceutical: 306.50 million yuan, with a flow rate of 18.56% and a price increase of 9.50% [2] - Tianyue Advanced: 218.43 million yuan, with a flow rate of 10.12% and a price increase of 20.00% [2] Stocks with Significant Fund Outflows - The stocks with the highest net outflows included: - Dongxin Co., with a net outflow of 311 million yuan and a price decrease of 0.04% [1] - Sainuo Medical: 219 million yuan outflow [1] - Haiguang Information: 129 million yuan outflow [1]

Group 1 - On September 5, 2025, a block trade of 266,900 shares of Borui Pharmaceutical was executed, with a total transaction value of 24.6483 million yuan, accounting for 1.47% of the total trading volume for the day [1] - The average transaction price was 92.35 yuan, representing a discount of 4.81% compared to the market closing price of 97.02 yuan [1] - The highest transaction price recorded was 97.02 yuan, while the lowest was 87.32 yuan [1] Group 2 - The block trade details indicate that on the same day, transactions were made at prices of 87.32 yuan and 97.02 yuan, with transaction amounts of 5.2392 million yuan and 13.4102 million yuan respectively [2] - The trading volume for the lower price was 6, while for the higher price, it was 13.82 [2] - Various brokerage firms were involved in these transactions, including Guotai Junan Securities and CITIC Securities [2]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-062 转债代码：118004 转债简称：博瑞转债 博瑞生物医药（苏州）股份有限公司 关于"博瑞转债"预计满足赎回条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债发行上市概况 经中国证券监督管理委员会证监许可[2021]3551 号文同意注册，博瑞生物医 药（苏州）股份有限公司（以下简称"公司"）于 2022 年 1 月 4 日向不特定对 象发行 465 万张可转换公司债券，每张面值为人民币 100 元，发行总额 46,500.00 万元。本次发行的可转换公司债券的期限为自发行之日起六年，即 2022 年 1 月 4 日至 2028 年 1 月 3 日。 经上海证券交易所自律监管决定书[2022]22 号文同意，公司 46,500.00 万元 可转换公司债券于 2022 年 1 月 27 日起在上海证券交易所挂牌交易，债券简称"博 瑞转债"，债券代码"118004"。 根据有关规定和《博瑞生物医药（苏州）股份有限公司向不特定对象发行 ...

证券代码：688166 证券简称：博瑞医药 公告编号：2025-061 博瑞生物医药（苏州）股份有限公司 关于参加 2025 年半年度科创板创新药行业集体 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 16 日（星期二）15:00-17:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 9 月 9 日（星期二）至 9 月 15 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 IR@bright-gene.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 博瑞生物医药（苏州）股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 年半年度报告。为便于广大投资者更全面深入地了解公司 2025 ...

Group 1 - On September 5, Borui Pharmaceutical experienced a 5.18% increase in stock price, reaching 93.19 CNY per share, with a trading volume of 675 million CNY and a turnover rate of 1.78%, resulting in a total market capitalization of 39.398 billion CNY [1] - Borui Pharmaceutical, established on October 26, 2001, and listed on November 8, 2019, is located in Suzhou Industrial Park, Jiangsu Province, and specializes in the research and production of high-end generic drugs and original new drugs [1] Group 2 - According to data from the top ten holdings of funds, one fund under Great Wall Fund has a significant position in Borui Pharmaceutical. The Great Wall SSE STAR 100 Index Enhanced A (023446) held 28,300 shares in the second quarter, accounting for 1.85% of the fund's net value, making it the ninth largest holding. The estimated floating profit today is approximately 130,100 CNY [2] - The Great Wall SSE STAR 100 Index Enhanced A (023446) was established on April 29, 2025, with a latest scale of 9.3575 million CNY and has achieved a return of 22.67% since inception [2]

Core Insights - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) has shown a strong increase of 1.32% as of September 5, 2025, with notable gains in constituent stocks such as Zai Lab (688266) up 5.31%, Junshi Biosciences (688180) up 3.89%, and Huatai Medical (688617) up 3.85% [1] - Novartis continues to invest in siRNA technology, recently entering into a significant business development deal with BGI Genomics, involving an upfront payment of $160 million and a total potential milestone value of $5.2 billion [1] - According to Dongfang Securities, the performance of innovative drugs and the industry chain is strong, driven by the commercialization of domestic innovative products and the potential for international expansion [1] Industry Overview - The Sci-Tech Innovation Board Biopharmaceutical Index comprises 50 large-cap companies in the biopharmaceutical, biomedical engineering, biomedicine, and other related sectors, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Innovation Board [2] - As of August 29, 2025, the top ten weighted stocks in the index account for 50.27% of the total index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the index, providing investors with exposure to the biopharmaceutical sector [2]